Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis
Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang
Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang
View: Text | PDF
Research Article Cell biology Metabolism Pulmonology

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis

  • Text
  • PDF
Abstract

Alveolar type 2 (AT2) progenitor cell exhaustion and impaired regenerative capacity are key pathogenic hallmarks in idiopathic pulmonary fibrosis (IPF). Nicotinamide adenine dinucleotide (NAD+) functions as a central regulator of cellular energy metabolism. We have previously reported that downregulation of NAD+-dependent sirtuin signaling contributes to the impaired progenitor cell function of IPF AT2 cells. In this study, we found that a key NAD+ biosynthesis enzyme, nicotinamide phosphoribosyltransferase (NAMPT), was significantly downregulated in IPF AT2 cells. NAMPT deficiency impaired AT2 renewal and enhanced lung fibrosis through downregulation of SIRT7 and SOD2, which resulted in increased oxidative stress, mitochondrial dysfunction, accumulated aberrant transitional cells, and impaired differentiation from AT2 to alveolar type 1 (AT1) cells. A mouse model with AT2-specific deletion of Nampt showed severely impaired AT2 renewal capacity and increased susceptibility to bleomycin lung injury. Activation of NAMPT by small-molecule activators promoted IPF AT2 renewal and reversed lung fibrosis in WT mice. NAMPT activation is a potentially promising therapeutic strategy for restoring AT2 progenitor cell function and halting or reversing progressive pulmonary fibrosis.

Authors

Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang

×

Figure 7

NAMPT activation in vivo promotes AT2 regeneration and attenuates lung fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
NAMPT activation in vivo promotes AT2 regeneration and attenuates lung f...
(A) Experimental layout: 10- to 12-week old (young) C57BL/6J mice were treated with 20 mg/kg NAT and 2.5 U/kg bleomycin, and lungs were collected on day 5. (B) Flow cytometric gating strategies for lung epithelial and AT2 cells. Epithelial cells were gated as EPCAM+CD31–CD34–CD45– cells among live cells and AT2 cells as CD24–Sca-1– cells within epithelial cell populations. (C–F) Percentages and total cell numbers of epithelial and AT2 cells per lung (n = 5/group; **P < 0.01, by unpaired, 2-tailed Student’s t test). (G) Experimental layout: 10- to 12-week-old (young) C57BL/6J mice were treated with 20 mg/kg NAT (from day –3 to day 3) and 1.25 U/kg bleomycin (day 0), and lungs were collected on day 21. (H) Trichrome staining (scale bars: 500 μm) and (I) hydroxyproline contents (n = 6–10/group; *P < 0.05, by ANOVA) were used to assess collagen deposition. (J) Experimental layout: 10- to 12-week-old (young) C57BL/6J mice were administrated 0.75 U/kg bleomycin (day 0) and treated with 20 mg/kg NAT at the fibrotic stage (days 10–16), and lungs were collected on day 21. (K) Trichrome staining (scale bar: 500 μm) and (L) hydroxyproline in the lungs (n = 4–10/group; *P < 0.05, by 1-way ANOVA) were used to assess fibrosis. (M) Experimental layout: Aged C57BL/6J mice were treated with 20 mg/kg NAT (from day –3 to day 3) and 0.75 U/kg bleomycin (day 0), and lungs were collected on day 21. (N) Trichrome staining (scale bar: 500 μm) and (O) hydroxyproline in the lungs (n = 5–14/group; **P < 0.01, by 1-way ANOVA) were used to assess fibrosis. Boxed areas are shown at higher magnification, scale bars: 500 μm (H, K, and N). Data are shown as the mean ± SEM. All experiments were repeated at least 3 times. Bleo, bleomycin.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts